Healthcare, Pharma & Life Sciences

Harbor Health Acquires 27 Village Medical Clinics in Houston

Houston – October 07, 2026 -- Harbor Health has signed an agreement to acquire 27 Village Medical clinics in Greater Houston, expanding its combined care-and-coverage model into Texas's largest city weeks before individual and family health plans launch there for the first time.

Harbor expands to a fifth Texas market with no-deductible plans

Houston becomes the fifth Texas market where Harbor both delivers care and sells insurance, joining Austin, Dallas, San Antonio and El Paso. Once the deal closes, expected by year-end, Harbor will operate nearly 70 clinics and more than double its number of physicians and advanced practice providers statewide. Financial terms of the acquisition were not disclosed.

Encompass Health Opens First Wholly Owned Maine Hospital in Bangor

Bangor, Maine – October 07, 2026 -- Encompass Health, the largest owner and operator of inpatient rehabilitation hospitals in the United States, has opened a 50-bed rehabilitation hospital in Bangor, Maine, and begun accepting patients.

Encompass Health enters Maine with first wholly owned facility in the state

The more than 54,000-square-foot Encompass Health Rehabilitation Hospital of Bangor marks the company's first wholly owned hospital in Maine. The company already operates New England Rehabilitation Hospital of Portland as a long-standing joint venture with MaineHealth.

BioMarin, Jazz, Otsuka CEOs Join NORD Summit Rare Disease Panel

Washington, D.C. – October 07, 2026 -- CNBC's Becky Quick will moderate a rare disease leadership dialogue featuring the CEOs of BioMarin, Jazz Pharmaceuticals and Otsuka North America Pharmaceutical alongside NORD CEO Pam Gavin, the National Organization for Rare Disorders announced.

Panel convenes three biopharma chiefs at NORD's Breakthrough Summit on October 26

The session, titled "Next Decade of Rare Disease: A CEO Leadership Dialogue," takes place at 11 a.m. ET on Monday, October 26, in Washington, D.C., during the three-day NORD Rare Diseases & Orphan Products Breakthrough Summit running October 25–27. Participants include Alexander Hardy, President and CEO of BioMarin; Renee Gala, President and CEO of Jazz Pharmaceuticals; Tarek Rabah, President and CEO of Otsuka North America Pharmaceutical; and NORD CEO Pam Gavin.

symplr Secures $280M Refinancing, Extends Debt Maturities to 2031

Houston – October 07, 2026 -- symplr has secured commitment letters for a refinancing package that delivers approximately $280 million in new capital and pushes out key debt maturities, with the transaction expected to close by the end of October.

Refinancing pushes first-lien debt maturity to December 2030

The deal extends the maturity of symplr's first-lien term loan and revolving credit facility to December 2030, while its second-lien term loans will now mature in June 2031. The enterprise healthcare operations software provider said the extended timeline reduces near-term cash interest requirements and strengthens liquidity.

Halozyme Expands argenx Deal to Eight Exclusive ENHANZE Targets

San Diego – – October 07, 2026 -- Halozyme Therapeutics (Nasdaq: HALO) has expanded its global collaboration and license agreement with argenx, adding two new exclusive targets for its ENHANZE drug-delivery platform and raising the partner's total exclusive target count from six to eight.

Halozyme adds two exclusive ENHANZE targets to argenx licensing deal

The expanded agreement builds on the companies' existing collaboration, which already delivered VYVGART Hytrulo, a subcutaneous treatment for myasthenia gravis (MG) and chronic inflammatory demyelinating polyneuropathy (CIDP). Under the new terms, Halozyme is eligible for milestone payments tied to development and regulatory progress on the additional targets, plus royalties on future net sales of any resulting products using ENHANZE.

CATCH Houston Wins Dual Awards in Federal Home-Based Care Challenge

Houston – October 07, 2026 -- CATCH Greater Houston has been named a Phase 1 winner in two of the ten awarded tracks of the Health at Home Challenge, a national competition run by the Administration for Community Living (ACL) within the U.S. Department of Health and Human Services.

CATCH secures dual recognition in federal care coordination competition

The nonprofit won as a community care hub within a national consortium led by the Oregon Wellness Network, spanning eight hubs across eight states, and separately as the designated lead of the Texas Hub Network, a statewide consortium formed with the Texas Health and Human Services Commission.

Enliven Secures FDA Alignment on Phase 3 CML Trial Design

Burlingame, Calif. – October 07, 2026 -- Enliven Therapeutics, Inc. (Nasdaq: ELVN) has reached alignment with the U.S. Food and Drug Administration on the final design of ENABLE-2, a pivotal Phase 3 trial testing relcobatinib against standard second-generation therapies in previously treated chronic myeloid leukemia (CML). The company remains on track to initiate the trial before year-end 2026.

FDA clears path for 450-patient head-to-head comparison

ENABLE-2 is designed to enroll approximately 450 adults with CML who have already received one or more tyrosine kinase inhibitors (TKIs). Participants will be randomized 1:1 to receive either relcobatinib at 80 mg once daily or an investigator-selected second-generation TKI -- dasatinib, nilotinib, or bosutinib. The primary endpoint is major molecular response (MMR) at Week 24, with MMR at Week 96 as a key secondary measure.

Caracal Co-Sponsors Inaugural NYC Military Collegiate Boxing Classic

New York – October 07, 2026 -- Caracal Products & Services will co-sponsor the inaugural NYC Collegiate Military Boxing Classic, 'Fight to Educate,' on Nov. 14, 2026, with proceeds directed to athletic programs at six U.S. military academies and colleges.

Six military schools will send boxing teams to compete in 12 matched bouts

The event, set for The Léman Ballroom at 41 Broad Street in New York from 5 p.m. to 10 p.m., will feature teams from The Citadel, the United States Air Force Academy, the United States Coast Guard Academy, the United States Military Academy (West Point), the United States Naval Academy, and Virginia Military Institute. Boxing legends Ray Mercer and Micky Ward will make guest appearances, alongside a VIP reception for alumni, supporters, and sponsors.

CMS Grants NTAP Reimbursement for icotec's CMORE CT Spine Implant

Altstätten, Switzerland and Boston – October 07, 2026 -- The Centers for Medicare & Medicaid Services has approved a New Technology Add-On Payment for icotec's CMORE® CT spine implant system, effective October 07, 2026, opening expanded reimbursement access for eligible hospitals treating Medicare patients.

CMS reimbursement decision follows April 2025 Break-Through Device Designation

icotec's CMORE® Cervicothoracic System received FDA Break-Through Device Designation in April 2025, a status that preceded the latest NTAP approval. The NTAP program provides eligible hospitals additional payment for qualifying technologies used in traditional Medicare procedures, applying here to specified spinal conditions and surgeries.

Highmark Health Names Karen Hanlon First Female CEO

Pittsburgh – October 07, 2026 -- Highmark Health's Board of Directors has appointed Karen Hanlon as chief executive officer and president, effective Jan. 1, 2027, making her the first female CEO in the organization's history. David Holmberg, who has led the Pittsburgh-based health system since 2014, will transition to executive chairman to oversee the leadership handover.

Hanlon inherits an enterprise that has doubled in size under the outgoing CEO

Highmark Health's revenue grew from approximately $17 billion in 2014 to a projected $35 billion by the end of 2026 during Holmberg's 12-year tenure. Hanlon, currently president, will take full responsibility for strategy, operations and growth across the organization's health plans, Allegheny Health Network (AHN) and diversified businesses.